Document Detail

Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma.
MedLine Citation:
PMID:  19903796     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended mitotane as monotherapy or combined with etoposide, doxorubicin and cisplatin or with streptozotocin as first-line systemic therapy. However, there is no evidence for any therapy beneficial in patients failing these therapies. Therefore, we evaluated the effects of the anti-VEGF antibody bevacizumab plus capecitabine as salvage therapy in ACC.
METHODS: Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with bevacizumab (5 mg/kg body weight i.v. every 21 days) and oral capecitabine (950 mg/m(2) twice daily for 14 days followed by 7 days of rest) in 2006-2008. Evaluation of tumour response was performed by imaging according to response evaluation criteria in solid tumours every 12 weeks.
RESULTS: Ten patients were treated with bevacizumab plus capecitabine. None of them experienced any objective response or stable disease. Two patients had to stop therapy after few weeks due to hand-foot syndrome, and three patients died on progressive disease within 12 weeks. Other adverse events were mild (grade I-II). Median survival after treatment initiation was 124 days.
CONCLUSIONS: Bevacizumab plus capecitabine has no activity in patients with very advanced ACC. Hence, this regimen cannot be recommended as a salvage therapy.
Sebastian Wortmann; Marcus Quinkler; Christian Ritter; Matthias Kroiss; Sarah Johanssen; Stefanie Hahner; Bruno Allolio; Martin Fassnacht
Related Documents :
25112526 - Successful use of octreotide as a chemoprotectant for prevention of peg-asparaginase-in...
19101406 - Recurrent disease four years after surgery and adjuvant chemotherapy.
16361806 - Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients wi...
19693536 - Feasibility and efficacy of capecitabine and folfiri in patients aged 65 years and olde...
25191856 - Ercc1 single nucleotide polymorphism c8092a, but not its expression is associated with ...
12968956 - Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemo...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-11-10
Journal Detail:
Title:  European journal of endocrinology / European Federation of Endocrine Societies     Volume:  162     ISSN:  1479-683X     ISO Abbreviation:  Eur. J. Endocrinol.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-01-25     Completed Date:  2010-02-17     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9423848     Medline TA:  Eur J Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  349-56     Citation Subset:  IM    
Endocrine and Diabetes Unit, Department of Internal Medicine I, University Hospital of Würzburg, University of Würzburg, Oberdürrbacher Strasse 6, 97080 Würzburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenal Cortex Neoplasms / drug therapy*
Adrenocortical Carcinoma / drug therapy*
Angiogenesis Inhibitors / administration & dosage,  adverse effects
Antibodies, Monoclonal / administration & dosage*,  adverse effects
Antibodies, Monoclonal, Humanized
Antimetabolites, Antineoplastic / administration & dosage,  adverse effects
Deoxycytidine / administration & dosage,  adverse effects,  analogs & derivatives*
Drug Therapy, Combination
Fluorouracil / administration & dosage,  adverse effects,  analogs & derivatives*
Middle Aged
Salvage Therapy / methods*
Severity of Illness Index
Survival Rate
Treatment Failure
Vascular Endothelial Growth Factor A / antagonists & inhibitors,  immunology
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antimetabolites, Antineoplastic; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 154361-50-9/capecitabine; 2S9ZZM9Q9V/bevacizumab; 51-21-8/Fluorouracil; 951-77-9/Deoxycytidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Isolated Addison's disease is unlikely to be caused by mutations in MC2R, MRAP or STAR, three genes ...
Next Document:  Effects of long-term L-thyroxine treatment on endothelial function and arterial distensibility in yo...